Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Boots pays pounds 175m for German skincare firm

Wednesday 10 September 1997 18:02 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Boots yesterday fulfilled a long-standing ambition to break into the German healthcare market when Boots Healthcare International paid pounds 175m for Merck's medical skincare company, Hermal Kurt Herrman, writes Nigel Cope.

The deal gives Boots a presence in the pounds 1.6bn German skincare market and follows its move into France last year, when it acquired the French skincare group Lutsia for pounds 115m.

David Thompson, finance director of Boots, said: "This is a significant acquisition for Boots, fulfilling a long-established strategic objective to achieve a presence for BHI in Germany. It underlines our confidence in the prospects of the division and our commitment to the long-term growth of the business." He said the deal was initially expected to be earnings- neutral.

Boots said the deal would open up the German market for BHI, its over- the-counter healthcare business whose products include Neurofen, Strepsils and the skin cream E45. Boots said it would consider other acquisitions for the business.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in